ADVERTISEMENT
ADVERTISEMENT

Strange Bedfellows in Transplant Drug Therapy

The Faculty of 1000 is a Web-based literature awareness tool published by BioMed Central. It provides a continuously updated insider's guide to the most important peer-reviewed papers within a range of research fields, based on the recommendations of a faculty of more than 1,400 leading researchers. Each issue, The Scientist publishes a list of top-rated papers from a specific subject area, as well as a short review of one or more of the listed papers. We also publish a selection of comments on

Leslie Pray
The Faculty of 1000 is a Web-based literature awareness tool published by BioMed Central. It provides a continuously updated insider's guide to the most important peer-reviewed papers within a range of research fields, based on the recommendations of a faculty of more than 1,400 leading researchers.

Each issue, The Scientist publishes a list of top-rated papers from a specific subject area, as well as a short review of one or more of the listed papers. We also publish a selection of comments on interesting recent papers from the Faculty of 1000's output. For more information visit www.facultyof1000.com.






Since the early 1980s, physicians have relied on the immunosuppressive drug cyclosporine (CsA) as a way to prevent allograft rejection in organ transplant patients. The problem with CsA, however, is that it also promotes tumor growth. Indeed, cancer kills many transplant patients. "It's a very bad situation to be in," says Edward...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT